What SEC filings does EyePoint, Inc. submit to the SEC?

EyePoint, Inc. (EYPT) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about EYPT?

A Form 4 for EYPT discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from EyePoint, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for EYPT?

The 10-K is EyePoint, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all EYPT SEC filings directly on EDGAR?

You can view all historical EyePoint, Inc. filings on the SEC EDGAR company page for EYPT. Each filing card on this page links directly to the original SEC document.

How often does EyePoint, Inc. file with the SEC?

EyePoint, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling EYPT shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

EYPT SEC Filing News — EyePoint, Inc.

Latest SEC filings for EyePoint, Inc. (EYPT) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-10.

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Duras…

Sector: Healthcare Industry: Biotechnology Market Cap: $36.9M CIK: 1314102

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for EYPT currently lean bearish. Of the 20 filing records displayed, 3 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 1 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

EYPT Filing Activity Snapshot 2026-03-24 — 2026-09-10

Insider Transactions (Form 4)

1 buy vs 2 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$5.50M

Lurker Nancy · 2026-07-21

421,235 shares · Form 144

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 7 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 7 filings in this group are Form 4s for EyePoint, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 7 insider filings shown, the breakdown is 2 option exercise, 2 open-market sale, 1 gift, 1 other reported transaction and 1 open-market purchase. 3 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Option exercise ×2: The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.
Open-market sale ×2: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Gift ×1: Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.
Other reported transaction ×1: The filing reports a transaction type that does not map to a routine purchase, sale, award or withholding.
Open-market purchase ×1: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Form 4 Gift Tax / Compensation Filing 2026-08-24

EYPT insider Form 4 filed for equity award, exercise, or tax withholding

Elston George (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`J`	Other transaction	5,000	—	—
`J`	Other transaction	5,000	—	—
`G`	Gift	64,953	—	—
`G`	Gift	64,953	—	—

Filing: Form 4 (Insider Transaction) Insider: Elston George (Chief Financial Officer) Shares: 139,906

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-08-18

EYPT insider Zaderej Karen L. (Director) bought 10,600 shares (~$52.3K)

Zaderej Karen L., listed as Director at EyePoint, Inc., reported an open-market purchase of 10,600 EYPT shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	10,600	$4.93	$52.3K

Filing: Form 4 (Insider Transaction) Insider: Zaderej Karen L. (Director) Shares: 10,600 Est. Value: $52.3K

View on SEC EDGAR → Open Filing Document →

Form 4 Option exercise Tax / Compensation Filing 2026-07-14

EYPT insider Form 4 filed for equity award, exercise, or tax withholding

Duker Jay S. (Director, President and CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	16,667	—	—
`F`	Tax withholding on vested shares	8,059	$14.72	$118.6K
`M`	Option exercise derivative · Restricted Stock Units	16,667	—	—

Filing: Form 4 (Insider Transaction) Insider: Duker Jay S. (Director, President and CEO) Shares: 24,726

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-02

EYPT insider Ribeiro Ramiro (Chief Medical Officer) sold 4,875 shares (~$73.2K)

Ribeiro Ramiro, listed as Chief Medical Officer at EyePoint, Inc., reported an open-market sale of 4,875 EYPT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	2,437	$8.26	$20.1K
`M`	Option exercise	2,438	$8.26	$20.1K
`S`	Open-market sale	2,437	$15.00	$36.6K
`S`	Open-market sale	2,438	$15.02	$36.6K
`M`	Option exercise derivative · Stock Option (Right to Buy)	2,437	—	—
`M`	Option exercise derivative · Stock Option (Right to Buy)	2,438	—	—

Filing: Form 4 (Insider Transaction) Insider: Ribeiro Ramiro (Chief Medical Officer) Shares: 4,875 Est. Value: $73.2K

View on SEC EDGAR → Open Filing Document →

Form 4 Option exercise Tax / Compensation Filing 2026-05-27

EYPT insider Form 4 filed for equity award, exercise, or tax withholding

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	7,500	—	—
`F`	Tax withholding on vested shares	3,627	$12.93	$46.9K
`M`	Option exercise derivative · Restricted Stock Units	7,500	—	—

Filing: Form 4 (Insider Transaction) Insider: Elston George (Chief Financial Officer) Shares: 11,127

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-04-20

EYPT insider Ribeiro Ramiro (Chief Medical Officer) sold 2,437 shares (~$36.6K)

Ribeiro Ramiro, listed as Chief Medical Officer at EyePoint, Inc., reported an open-market sale of 2,437 EYPT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	2,437	$8.26	$20.1K
`S`	Open-market sale	2,437	$15.00	$36.6K
`M`	Option exercise derivative · Stock Option (Right to Buy)	2,437	—	—

Filing: Form 4 (Insider Transaction) Insider: Ribeiro Ramiro (Chief Medical Officer) Shares: 2,437 Est. Value: $36.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Other reported transaction Tax / Compensation Filing 2026-03-24

EYPT insider Form 4 filed for equity award, exercise, or tax withholding

The filing reports a transaction type that does not map to a routine purchase, sale, award or withholding.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`J`	Other transaction	76,766	$13.11	$1.01M
`J`	Other transaction	76,766	$13.11	$1.01M
`J`	Other transaction derivative · Stock Option (Right to Buy)	52,500	$8.75	$459.4K
`J`	Other transaction derivative · Stock Option (Right to Buy)	52,500	$8.75	$459.4K
`J`	Other transaction derivative · Stock Option (Right to Buy)	97,500	$9.57	$933.1K
`J`	Other transaction derivative · Stock Option (Right to Buy)	97,500	$9.57	$933.1K

Filing: Form 4 (Insider Transaction) Insider: Duker Jay S. (Director, President and CEO) Shares: 153,532

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 2 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. EyePoint, Inc. has 2 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Large Proposed Insider Sale 2026-07-21

EYPT Form 144 filed for proposed insider sale by Lurker Nancy (421,235 shares) ~$5.50M

Lurker Nancy filed a Form 144 with the SEC indicating intent to sell EYPT (EyePoint, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: Lurker Nancy Shares: 421,235 Est. Value: $5.50M

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-04-17

EYPT Form 144 filed for proposed insider sale by Ramiro Ribeiro (9,750 shares) ~$144.4K

Ramiro Ribeiro filed a Form 144 with the SEC indicating intent to sell EYPT (EyePoint, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Ramiro Ribeiro Shares: 9,750 Est. Value: $144.4K

View on SEC EDGAR → Open Filing Document →

Material Events 9 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 9 in this period for EyePoint, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-10